Bayer is deepening its ties with Harvard and MIT's Broad Institute, delving into cardiovascular genomics in hopes of spotlighting new therapeutic approaches to deadly diseases.
Pennsylvania nanotech company Genisphere announced this week that in preclinical studies its 3DNA platform has successfully treated a cataract surgery complication called posterior capsular opacification.
Are two breakthrough cancer drugs better than one? Pharma giant Merck and Waltham, MA-based Syndax plan to find out in a Phase Ib/II study matching the tiny biotech's entinostat with Keytruda, Merck's big anti-PD-1 therapy newly approved for melanoma.
A team of researchers is developing a new form of microbubble delivery, deploying ultrasound to implode the bubbles into several smaller nanobubbles that can cross biological barriers due to their size and release the payloads within the target area.
Scientists at Japan's Kyushu University claim to have developed a technique for dispersing carbon nanotubes made of graphene while preserving their desirable properties like conductivity, durability and length.
The developer of a novel drug delivery platform for nitric oxide just raised $50 million in a financing round led by Irish life science investment fund Malin.
Researchers at the University of Illinois-Chicago have developed a nanoparticle-based robot that can detect humidity thanks to the use of bacterial spores and a form of carbon known as graphene.
Novartis, a leader among companies using the immune system to fight cancer, is betting up to $750 million on a promising therapeutic approach from Aduro Biotech, widening its arsenal of potential treatments.
Orthopedics specialist Zimmer is trying to expand the market for its artificial joints by appealing to younger patients. Its strategies to do so are on display at the annual meeting of the American Academy of Orthopaedic Surgeons meeting in Las Vegas.
Startup TVA Medical boasted about a recent study which found that its clinical-stage device to give chronic kidney disease patients vascular access to a hemodialysis machine was successful 97% of the time.